Thyrocare Technologies Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 28.4%)
- Efficient capital deployment (ROCE 35.4%)
- Virtually debt-free
- Regular dividends — yield 2%
Concerns
- High premium to book value (P/B 15.5x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
THYROCARE · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 71.11% | 71.11% | 71.11% | 71.11% | 71.06% | 71.06% |
| FII | 3.35% | 2.90% | 2.49% | 1.93% | 2.77% | 2.41% |
| DII | 13.89% | 14.88% | 14.89% | 14.79% | 14.68% | 14.97% |
| Public | 11.64% | 11.11% | 11.49% | 12.15% | 11.49% | 11.57% |
Corporate Events
Thyrocare Technologies Limited has informed the Exchange about Board Meeting to be held on Thursday, October 29, 2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the quarter and half year ended September 30, 2026
Thyrocare Technologies Limited has informed the Exchange about Board Meeting to be held on July 23, 2026 to inter-alia consider and approve the Unaudited Standalone and Consolidated Financial results of the Company for the quarter ended June 30, 2026
Dividend - Rs 7 Per Share
Bonus 2:1
Interim Dividend - Rs 7 Per Share
Dividend - Rs 21 Per Share
Dividend - Rs 18 Per Share
Latest News
All newsThyrocare acquires stake in Trovera as part of Nueclear sale
*Thyrocare acquires stake in Trovera as part of Nueclear sale*. Thyrocare Technologies has acquired compulsorily convertible preference shares in Trovera Healthcare Private Limited. This move is part of the consideration for selling its wholly-owned subsidiary, Nueclear Healthcare Limited. The transaction reflects a strategic realignment in the diagnostics space. 📊 *STOCKS:* $THYROCARE | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #Acquisition
Thyrocare promoter sells 1.58 crore shares
*Thyrocare promoter offloads 1.58 crore shares.* Docon Technologies Private Limited sold **1,57,69,696** equity shares of the company. The stake sale by the promoter entity may signal reduced confidence or fund realignment. Traders should monitor for potential price volatility. 📊 *STOCKS:* $THYROCARE | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #PromoterSelling
Thyrocare announces outcome of September 21 board meeting
*Thyrocare announces outcome of September 21 board meeting.* The company disclosed updates following its board meeting held on September 21, 2026. Specific details were not outlined in the filing. Further announcements may follow in due course. 📊 *STOCKS:* $THYROCARE | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Corporate
Thyrocare publishes newspaper notice for fund raising
*Thyrocare publishes newspaper notice for fund raising.* The company has issued a newspaper publication related to a fund raising activity, as per a corporate filing on NSE. This is a procedural step and does not disclose size or timing. Such notices are typically routine and informational. 📊 *STOCKS:* $THYROCARE | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #Funding
Thyrocare announces 1.75 crore equity shares update
*Thyrocare announces 1.75 crore equity shares update.* The company filed updated equity share data with the NSE, disclosing **1,75,00,000** shares. This reflects routine regulatory disclosure with no immediate financial impact. Investors should monitor for further corporate developments. 📊 *STOCKS:* THYROCARE | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #CorporateFiling
Thyrocare ₹1,000 crore block deal planned
*Thyrocare ₹1,000 crore block deal planned*. A block deal involving **1.5 crore shares** at a floor price of **₹630–631** may result in a **₹1,000 crore** stake sale. The transaction signals significant promoter or investor exit. Such bulk deals can impact short-term price volatility and market sentiment. 📊 *STOCKS:* $THYROCARE | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #BlockDeal
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹224 Cr 14.3% | ₹196 Cr 9.7% | ₹217 Cr 12.4% | ₹193 Cr 3.2% | ₹187 Cr 12.7% | ₹166 Cr 6.2% | ₹177 Cr 12.7% | ₹157 Cr |
| Op. Profit | ₹75 Cr 29.3% | ₹58 Cr 18.3% | ₹71 Cr 22.4% | ₹58 Cr 1.8% | ₹57 Cr 35.7% | ₹42 Cr 12.5% | ₹48 Cr 14.3% | ₹42 Cr |
| OPM | 34.0% 13.3% | 30.0% 9.1% | 33.0% 10.0% | 30.0% 0.0% | 30.0% 20.0% | 25.0% 7.4% | 27.0% 0.0% | 27.0% |
| Net Profit | ₹49 Cr 75.0% | ₹28 Cr 41.7% | ₹48 Cr 26.3% | ₹38 Cr 72.7% | ₹22 Cr 15.8% | ₹19 Cr 26.9% | ₹26 Cr 8.3% | ₹24 Cr |
| EPS (₹) | 2.96 62.6% | 1.82 39.7% | 3.02 23.3% | 2.45 80.1% | 1.36 13.3% | 1.2 28.6% | 1.68 10.5% | 1.52 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹829 Cr 20.7% | ₹687 Cr 20.1% | ₹572 Cr 8.5% | ₹527 Cr 10.5% | ₹589 Cr 19.0% | ₹495 Cr 14.1% | ₹434 Cr 7.7% | ₹403 Cr 13.2% | ₹356 Cr 17.1% | ₹304 Cr |
| Expenses | ₹566 Cr 13.7% | ₹498 Cr 15.3% | ₹432 Cr 7.2% | ₹403 Cr 14.2% | ₹353 Cr 9.3% | ₹323 Cr 23.8% | ₹261 Cr 4.8% | ₹249 Cr 17.5% | ₹212 Cr 12.2% | ₹189 Cr |
| Op. Profit | ₹263 Cr 38.4% | ₹190 Cr 35.7% | ₹140 Cr 13.8% | ₹123 Cr 47.9% | ₹236 Cr 38.0% | ₹171 Cr 1.7% | ₹174 Cr 13.0% | ₹154 Cr 6.2% | ₹145 Cr 26.1% | ₹115 Cr |
| OPM | 32.0% 14.3% | 28.0% 16.7% | 24.0% 4.3% | 23.0% 42.5% | 40.0% 14.3% | 35.0% 12.5% | 40.0% 5.3% | 38.0% 7.3% | 41.0% 7.9% | 38.0% |
| Other Income | ₹12 Cr 20.0% | ₹15 Cr 66.7% | ₹9 Cr 0.0% | ₹9 Cr 69.0% | ₹29 Cr 141.7% | ₹12 Cr 1100.0% | ₹1 Cr 90.9% | ₹11 Cr 47.6% | ₹21 Cr 240.0% | ₹-15 Cr |
| Interest | ₹4 Cr 0.0% | ₹4 Cr 33.3% | ₹6 Cr 20.0% | ₹5 Cr 66.7% | ₹3 Cr 200.0% | ₹1 Cr 50.0% | ₹2 Cr 100.0% | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹59 Cr 7.3% | ₹55 Cr 17.0% | ₹47 Cr 20.5% | ₹39 Cr 14.7% | ₹34 Cr 13.3% | ₹30 Cr 6.3% | ₹32 Cr 23.1% | ₹26 Cr 30.0% | ₹20 Cr 11.1% | ₹18 Cr |
| PBT | ₹213 Cr 46.9% | ₹145 Cr 51.0% | ₹96 Cr 7.9% | ₹89 Cr 61.0% | ₹228 Cr 50.0% | ₹152 Cr 8.6% | ₹140 Cr 1.4% | ₹138 Cr 4.8% | ₹145 Cr 76.8% | ₹82 Cr |
| Tax % | 24.0% 36.8% | 38.0% 35.7% | 28.0% 3.7% | 27.0% 17.4% | 23.0% 11.5% | 26.0% 29.7% | 37.0% 2.6% | 38.0% 5.6% | 36.0% 25.0% | 48.0% |
| Net Profit | ₹163 Cr 79.1% | ₹91 Cr 31.9% | ₹69 Cr 7.8% | ₹64 Cr 63.6% | ₹176 Cr 55.8% | ₹113 Cr 28.4% | ₹88 Cr 3.5% | ₹85 Cr 8.6% | ₹93 Cr 116.3% | ₹43 Cr |
| EPS (₹) | 10.24 77.8% | 5.76 29.4% | 4.45 9.6% | 4.06 63.4% | 11.1 55.7% | 7.13 27.8% | 5.58 3.7% | 5.38 7.1% | 5.79 117.7% | 2.66 |
| Div Payout | 137.0% 12.3% | 122.0% 9.6% | 135.0% 8.8% | 148.0% 228.9% | 45.0% 61.5% | 117.0% 290.0% | 30.0% 75.8% | 124.0% 113.8% | 58.0% 53.6% | 125.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹159 Cr 200.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 1.9% | ₹54 Cr 0.0% | ₹54 Cr |
| Reserves | ₹426 Cr 13.8% | ₹494 Cr 4.2% | ₹474 Cr 1.5% | ₹481 Cr 1.5% | ₹474 Cr 26.7% | ₹374 Cr 19.1% | ₹314 Cr 17.8% | ₹382 Cr 2.1% | ₹390 Cr 10.2% | ₹354 Cr |
| Borrowings | ₹51 Cr 104.0% | ₹25 Cr 40.5% | ₹42 Cr 82.6% | ₹23 Cr 9.5% | ₹21 Cr 162.5% | ₹8 Cr 33.3% | ₹12 Cr 500.0% | ₹2 Cr | ₹0 Cr | ₹0 Cr |
| Other Liabilities | ₹111 Cr 8.3% | ₹121 Cr 61.3% | ₹75 Cr 1.4% | ₹74 Cr 23.3% | ₹60 Cr 43.4% | ₹106 Cr 17.8% | ₹90 Cr 143.2% | ₹37 Cr 2.8% | ₹36 Cr 20.0% | ₹30 Cr |
| Total Liabilities | ₹747 Cr 7.8% | ₹693 Cr 7.6% | ₹644 Cr 1.9% | ₹632 Cr 4.1% | ₹607 Cr 12.2% | ₹541 Cr 15.4% | ₹469 Cr 1.3% | ₹475 Cr 0.8% | ₹479 Cr 9.4% | ₹438 Cr |
Assets | ||||||||||
| Fixed Assets | ₹317 Cr 6.7% | ₹297 Cr 2.9% | ₹306 Cr 4.1% | ₹294 Cr 3.2% | ₹285 Cr 12.6% | ₹253 Cr 5.9% | ₹269 Cr 8.5% | ₹294 Cr 1.7% | ₹299 Cr 15.4% | ₹259 Cr |
| CWIP | ₹3 Cr 78.6% | ₹14 Cr 366.7% | ₹3 Cr 50.0% | ₹2 Cr 33.3% | ₹3 Cr 62.5% | ₹8 Cr 60.0% | ₹5 Cr 400.0% | ₹1 Cr | ₹0 Cr 100.0% | ₹17 Cr |
| Investments | ₹177 Cr 9.3% | ₹162 Cr 0.0% | ₹162 Cr 12.5% | ₹144 Cr 1.4% | ₹146 Cr 15.9% | ₹126 Cr 40.0% | ₹90 Cr 5.3% | ₹95 Cr 20.8% | ₹120 Cr 15.4% | ₹104 Cr |
| Other Assets | ₹250 Cr 13.6% | ₹220 Cr 27.2% | ₹173 Cr 9.9% | ₹192 Cr 11.0% | ₹173 Cr 12.3% | ₹154 Cr 46.7% | ₹105 Cr 25.0% | ₹84 Cr 40.0% | ₹60 Cr 3.4% | ₹58 Cr |
| Total Assets | ₹747 Cr 7.8% | ₹693 Cr 7.6% | ₹644 Cr 1.9% | ₹632 Cr 4.1% | ₹607 Cr 12.2% | ₹541 Cr 15.4% | ₹469 Cr 1.3% | ₹475 Cr 0.8% | ₹479 Cr 9.4% | ₹438 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹213 Cr 11.5% | ₹191 Cr 13.7% | ₹168 Cr 30.2% | ₹129 Cr 14.2% | ₹113 Cr 1.7% | ₹115 Cr 31.5% | ₹168 Cr 68.0% | ₹100 Cr 6.5% | ₹107 Cr 18.9% | ₹90 Cr |
| Investing CF | ₹-23 Cr 56.6% | ₹-53 Cr 41.8% | ₹-91 Cr 133.3% | ₹-39 Cr 62.5% | ₹-24 Cr 51.0% | ₹-49 Cr 5000.0% | ₹1 Cr 108.3% | ₹-12 Cr 72.1% | ₹-43 Cr 2.4% | ₹-42 Cr |
| Financing CF | ₹-170 Cr 30.8% | ₹-130 Cr 52.9% | ₹-85 Cr 1.2% | ₹-86 Cr 3.4% | ₹-89 Cr 43.5% | ₹-62 Cr 62.4% | ₹-165 Cr 75.5% | ₹-94 Cr 46.9% | ₹-64 Cr 30.6% | ₹-49 Cr |
| Net Cash Flow | ₹21 Cr 162.5% | ₹8 Cr 200.0% | ₹-8 Cr 300.0% | ₹4 Cr | ₹0 Cr 100.0% | ₹4 Cr 0.0% | ₹4 Cr 180.0% | ₹-5 Cr | ₹0 Cr | ₹0 Cr |
| Free Cash Flow | ₹198 Cr 35.6% | ₹146 Cr 36.4% | ₹107 Cr 21.6% | ₹88 Cr 11.1% | ₹99 Cr 6.5% | ₹93 Cr 41.1% | ₹158 Cr 159.0% | ₹61 Cr 3.2% | ₹63 Cr 18.9% | ₹53 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 33d 15.4% | 39d 39.3% | 28d 52.5% | 59d 1.7% | 58d 75.8% | 33d 135.7% | 14d 27.3% | 11d 10.0% | 10d 25.0% | 8d |
| Inventory Days | 81d 9.0% | 89d 14.4% | 104d 67.7% | 62d 17.0% | 53d 1.9% | 52d 18.8% | 64d 6.7% | 60d 9.1% | 66d 1.5% | 65d |
| Days Payable | 109d 25.3% | 146d 65.9% | 88d 63.0% | 54d 50.0% | 36d 35.7% | 56d 17.6% | 68d 172.0% | 25d 0.0% | 25d 316.7% | 6d |
| Cash Conv. Cycle | 4d 122.2% | -18d 140.9% | 44d 34.3% | 67d 10.7% | 75d 158.6% | 29d 190.0% | 10d 78.3% | 46d 8.0% | 50d 25.4% | 67d |
| Working Capital Days | 19d 46.2% | 13d 85.7% | 7d 77.4% | 31d 24.4% | 41d 115.8% | 19d 337.5% | -8d 128.6% | 28d 180.0% | 10d 47.4% | 19d |
| ROCE | 35.0% 40.0% | 25.0% 38.9% | 18.0% 5.9% | 17.0% 59.5% | 42.0% 16.7% | 36.0% 2.9% | 35.0% 16.7% | 30.0% 9.1% | 33.0% 17.9% | 28.0% |
Source: Screener.in · Lower days = better efficiency